Phentolamine

HY-12717 Cat. No.: CAS No.: 50-60-2 Molecular Formula: $C_{17}H_{19}N_3O$ Molecular Weight: 281.35

Target: Adrenergic Receptor

GPCR/G Protein; Neuronal Signaling Pathway:

Storage: Powder -20°C 3 years

> -80°C In solvent 6 months

> > -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (444.29 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.5543 mL	17.7715 mL	35.5429 mL
	5 mM	0.7109 mL	3.5543 mL	7.1086 mL
	10 mM	0.3554 mL	1.7771 mL	3.5543 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Phentolamine is a potent, selective and orally active $\alpha 1$ adrenergic and $\alpha 2$ adrenergic receptor antagonist. Phentolamine can be used for the research of erectile dysfunction ^{[1][2][3]} .		
IC ₅₀ & Target	α adrenergic receptor		
In Vivo	Phentolamine (5-20 mg/kg; i.p.) effectively inhibits the seizures elicited by strychnine (2 mg/kg, i.p.) and attenuates the seizure-potentiating effect of DOPS (4 mg/kg, i.p.) in mouse ^[2] . Phentolamine (1 mg/kg; i.p.) increases insulin secretion by inhibition of b-cell a2A-adrenoceptors in mouse ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	WT mice ^[3]	
	Dosage:	1 mg/kg	
	Administration:	IP	

Result:	Reduced blood glucose and increased insulin levels.	

CUSTOMER VALIDATION

- Neurosci Bull. 2023 Jun 19.
- J Endocrinol. 2020 Mar;244(3):459-471.
- bioRxiv. 2023 Oct 13.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

- [1]. Goldstein II. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res. 2000 Mar;12(S1):S75-S80
- [2]. Amabeoku G, et al. Strychnine-induced seizures in mice: the role of noradrenaline. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):753-63.
- [3]. Fagerholm V, et al. alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice. Br J Pharmacol. 2008 Jul;154(6):1287-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA